Copyright
©The Author(s) 2025.
World J Exp Med. Sep 20, 2025; 15(3): 108034
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.108034
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.108034
Table 5 Diagnostic performance of microRNAs and other tumor biomarkers in breast cancer patients (grade III) relative to the control group
| Parameters | Area under the curve | Cut-off value | Sensitivity (%) | Specificity (%) | P value | 95%CI |
| MiR-21 | 1.000 | 2.73 | 100.0 | 100.0 | 0.000 | 1.000-1.000 |
| MiR-221 | 0.946 | 1.20 | 100.0 | 75.0 | 0.000 | 0.886-1.000 |
| MiR-1246 | 0.990 | 2.035 | 95.8 | 95.0 | 0.000 | 0.969-1.000 |
| MiR-145 | 0.978 | 0.35 | 87.5 | 100.0 | 0.000 | 0.945-1.000 |
| MiR-382 | 0.950 | 0.305 | 79.2 | 95.0 | 0.000 | 0.894-1.000 |
| 8-hydroxy-2′-deoxyguanosine | 0.994 | 1822.00 | 100.0 | 95.0 | 0.000 | 0.979-1.000 |
| Cancer antigen 15-3 | 0.985 | 178.00 | 87.5 | 100.0 | 0.000 | 0.961-1.000 |
| MiR-382 + MiR-221 | 0.992 | - | 95.8 | 100.0 | 0.000 | 0.973-1.000 |
- Citation: El-Toukhy SE, Nabih HK, Kamel MM, Elmasry H, El-Daly SM. Circulating microRNAs and serum proteins in breast cancer patients: Diagnostic relevance and grade-specific expression patterns. World J Exp Med 2025; 15(3): 108034
- URL: https://www.wjgnet.com/2220-315X/full/v15/i3/108034.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i3.108034